granisetron oral / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
granisetron oral / Generic mfg.
SAKK 90/95, NCT00003213: Drugs to Reduce the Side Effects of Chemotherapy

Completed
3
267
Europe
dexamethasone, dexamethasone acetate, granisetron hydrochloride, Kytril®, metoclopramide hydrochloride, Metozolv®
Swiss Group for Clinical Cancer Research
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
04/99
08/99
NCT00475085: Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Completed
3
1021
US
aprepitant, Emend, dexamethasone, Decadron, granisetron hydrochloride, Kytril, palonosetron hydrochloride, Aloxi, prochlorperazine, Compazine, placebo
Joseph Roscoe, National Cancer Institute (NCI)
Nausea
12/12
 
NCT00005024: Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

Unknown status
3
NA
carboplatin, cyclophosphamide, doxorubicin hydrochloride, granisetron hydrochloride
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT01500226 / 2010-022746-24: Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
3
1369
US
Rolapitant, Varubi, Granisetron, Kytril, Granisol, Dexamethasone, Decadron, Placebo, Placebo to match Rolapitant
Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
02/14
02/14
NCT01500213 / 2010-022743-37: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Completed
3
555
US
Rolapitant, Varubi, Granisetron, Kytril, Granisol, Dexamethasone, Decadron, Placebo, Placebo to match Rolapitant
Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
03/14
03/14
NCT01499849 / 2010-022742-25: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Completed
3
532
US
Rolapitant, Varubi, Granisetron, Kytril, Granisol, dexamethasone, Decadron, Placebo, Placebo to match Rolapitant
Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
05/14
05/14
NCT02116530: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Completed
3
401
US
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
04/15
11/15
NCT03817970: Cisplatin Disposition and Kidney Injury

Recruiting
3
72
US
Granisetron, Kytril, Ondansetron, Zofran, Palonosetron, Aloxi
University of Colorado, Denver, Memorial Sloan Kettering Cancer Center, Rutgers University, National Institute of General Medical Sciences (NIGMS)
Nephrotoxicity
09/25
12/26

Download Options